JP2011510620A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011510620A5 JP2011510620A5 JP2010543520A JP2010543520A JP2011510620A5 JP 2011510620 A5 JP2011510620 A5 JP 2011510620A5 JP 2010543520 A JP2010543520 A JP 2010543520A JP 2010543520 A JP2010543520 A JP 2010543520A JP 2011510620 A5 JP2011510620 A5 JP 2011510620A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6301508P | 2008-01-28 | 2008-01-28 | |
| US61/063,015 | 2008-01-28 | ||
| PCT/EP2009/050850 WO2009095372A1 (en) | 2008-01-28 | 2009-01-26 | Methods and compositions using klotho-fgf fusion polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011510620A JP2011510620A (ja) | 2011-04-07 |
| JP2011510620A5 true JP2011510620A5 (ja) | 2011-09-08 |
| JP5627469B2 JP5627469B2 (ja) | 2014-11-19 |
Family
ID=40492768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010543520A Expired - Fee Related JP5627469B2 (ja) | 2008-01-28 | 2009-01-26 | クロトー−ｆｇｆ融合ポリペプチドを使用する方法および組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8481031B2 (ja) |
| EP (1) | EP2247614B1 (ja) |
| JP (1) | JP5627469B2 (ja) |
| KR (1) | KR20100118126A (ja) |
| CN (1) | CN102015760B (ja) |
| AR (1) | AR070690A1 (ja) |
| AU (1) | AU2009209696B2 (ja) |
| BR (1) | BRPI0906722A2 (ja) |
| CA (2) | CA2854933A1 (ja) |
| CL (1) | CL2009000166A1 (ja) |
| CO (1) | CO6300826A2 (ja) |
| CR (1) | CR11580A (ja) |
| EA (1) | EA201001204A1 (ja) |
| EC (1) | ECSP10010372A (ja) |
| ES (1) | ES2479417T3 (ja) |
| IL (1) | IL207161A0 (ja) |
| MA (1) | MA32031B1 (ja) |
| MX (1) | MX2010008206A (ja) |
| PE (1) | PE20091405A1 (ja) |
| TW (1) | TW200936156A (ja) |
| WO (1) | WO2009095372A1 (ja) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
| TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| JOP20190083A1 (ar) * | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| NZ592009A (en) | 2008-10-10 | 2012-11-30 | Amgen Inc | Fgf21 mutants and uses thereof |
| AU2010246038A1 (en) | 2009-05-05 | 2011-12-01 | Amgen Inc. | FGF21 mutants and uses thereof |
| SI3248610T1 (sl) * | 2009-05-05 | 2024-03-29 | Amgen Inc., | Mutanti fgf21 in njihove uporabe |
| US8324160B2 (en) * | 2009-06-17 | 2012-12-04 | Amgen Inc. | Chimeric polypeptides and uses thereof |
| CN102656266B (zh) * | 2009-10-15 | 2016-08-03 | 霍夫曼-拉罗奇有限公司 | 具有改变的受体特异性的嵌合成纤维细胞生长因子 |
| US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
| CA2782814A1 (en) * | 2009-12-02 | 2011-06-09 | Amgen Inc. | Binding proteins that bind to human fgfr1c, human .beta.-klotho and both human fgfr1c and human .beta.-klotho |
| UA109888C2 (uk) * | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| CA2783555A1 (en) | 2009-12-16 | 2011-07-14 | Eli Lilly And Company | Therapeutic uses of soluble alpha-klotho |
| EP3670534A3 (en) | 2010-04-15 | 2020-09-09 | Amgen Inc. | Human fgf receptor and beta-klotho binding proteins |
| WO2011144756A1 (en) | 2010-05-21 | 2011-11-24 | Xl-Protein Gmbh | Biosynthetic proline/alanine random coil polypeptides and their uses |
| HUE052944T2 (hu) * | 2010-06-25 | 2021-05-28 | Shire Human Genetic Therapies | Terápiás hatóanyagok központi idegrendszerbe juttatása |
| CN102465182A (zh) * | 2010-10-29 | 2012-05-23 | 株式会社爱茉莉太平洋 | 检测皮肤活性物质的检测试剂盒和检测皮肤活性物质的方法 |
| EP3597666A3 (en) | 2011-07-01 | 2020-04-22 | NGM Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| WO2013027191A1 (en) * | 2011-08-25 | 2013-02-28 | Novartis Ag | Methods and compositions using fgf23 fusion polypeptides |
| TWI478002B (zh) * | 2012-02-09 | 2015-03-21 | Univ Nat Sun Yat Sen | 一種篩選治療或預防帕金森氏症及其併發症之候選藥物的方法 |
| US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
| ES2828505T3 (es) | 2012-11-28 | 2021-05-26 | Ngm Biopharmaceuticals Inc | Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| KR20150104579A (ko) * | 2012-12-27 | 2015-09-15 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법 |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| ES2714127T3 (es) * | 2013-10-24 | 2019-05-27 | Tokyo Metropolitan Geriatric Hospital And Inst Of Gerontology | Células madre musculares o mioblastos, procedimiento de cribado de sustancias que participan en la conversión metabólica usando las mismas, y composición farmacéutica que comprende la sustancia obtenida de dicho procedimiento del cribado |
| US10369199B2 (en) | 2013-10-28 | 2019-08-06 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of cancer |
| SG11201606018UA (en) | 2014-01-24 | 2016-08-30 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
| CA2943361A1 (en) * | 2014-03-28 | 2015-10-01 | New York University | Fgf23 fusion proteins |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| AU2015277438B2 (en) | 2014-06-16 | 2020-02-27 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| SG11201702757YA (en) | 2014-10-23 | 2017-05-30 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| EA201791238A1 (ru) * | 2014-12-04 | 2018-02-28 | Новартис Аг | Способы и композиции, в которых используются варианты полипептидов klotho |
| CN105838661B (zh) * | 2014-12-30 | 2020-11-10 | 深圳市第二人民医院 | Klotho基因编辑在异种肾脏移植中的应用 |
| CN107405382A (zh) | 2015-02-06 | 2017-11-28 | 加利福尼亚大学董事会 | 用于改善认知的方法和组合物 |
| ES2750008T3 (es) * | 2015-02-27 | 2020-03-24 | Apceth Gmbh & Co Kg | Células madre mesenquimatosas modificadas genéticamente que expresan klotho |
| WO2017008016A1 (en) * | 2015-07-09 | 2017-01-12 | The Board Of Regents Of The University Of Texas System | Nanoparticles containing extracellular matrix for drug delivery |
| WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| EP3888672A1 (en) | 2015-11-09 | 2021-10-06 | NGM Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| CN116478907A (zh) * | 2016-06-02 | 2023-07-25 | 克洛索治疗有限公司 | 治疗性重组klotho蛋白及其组合物和方法 |
| CA3034399A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| JP7244923B2 (ja) * | 2016-11-22 | 2023-03-23 | クロトー セラピューティクス インコーポレイテッド | 新規な組換えクロトータンパク質ならびにそれを含む組成物 |
| EP3649157A4 (en) | 2017-07-06 | 2021-07-28 | Yale University | COMPOSITIONS AND METHODS OF TREATMENT OR PREVENTION OF DISEASES RELATED TO ENDOCRINE FGF |
| KR20200095538A (ko) * | 2017-12-06 | 2020-08-10 | 클로토 테라퓨틱스, 아이엔씨. | 클로토 단백질 수준을 평가하고 증가시키기 위한 산물 및 방법 |
| CA3085322A1 (en) * | 2017-12-13 | 2019-06-20 | Yale University | Compositions and methods for treating or preventing endocrine fgf23-linked diseases |
| CN108434441A (zh) * | 2018-04-17 | 2018-08-24 | 哈尔滨博翱生物医药技术开发有限公司 | 新型成纤维细胞生长因子-21类似物在治疗弥漫性间质性肺脏疾病中的应用 |
| CN109722480B (zh) * | 2018-05-17 | 2022-04-26 | 上海交通大学 | 一种非小细胞肺癌检测试剂盒及其应用 |
| US11969460B2 (en) | 2018-06-08 | 2024-04-30 | Saint Louis University | Methods and compositions for treating decreased cognitive ability |
| US11891615B2 (en) | 2020-06-10 | 2024-02-06 | Gail Marion Humble | Process to produce Klotho protein in vitro |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6406A (en) | 1849-05-01 | Artificial teeth | ||
| US853A (en) | 1838-07-24 | Jesse reed | ||
| IL71691A (en) | 1984-04-27 | 1991-04-15 | Yeda Res & Dev | Production of interferon-ypsilon |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US5266561A (en) | 1988-01-11 | 1993-11-30 | Amylin Pharmaceuticals, Inc. | Treatment of type 2 diabetes mellitus |
| CA2071867A1 (en) | 1989-11-06 | 1991-05-07 | Edith Mathiowitz | Method for producing protein microspheres |
| AU646877B2 (en) | 1990-06-15 | 1994-03-10 | Scios Nova Inc. | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
| US5408038A (en) * | 1991-10-09 | 1995-04-18 | The Scripps Research Institute | Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US5420112A (en) | 1992-06-12 | 1995-05-30 | Lewis; Michael E. | Prevention and treatment of peripheral neuropathy |
| US5541094A (en) | 1992-09-25 | 1996-07-30 | E. I. Du Pont De Nemours And Company | Glyoxylic acid/aminomethylphosphonic acid mixtures prepared using a microbial transformant |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| US6187992B1 (en) | 1994-12-05 | 2001-02-13 | Merck & Co., Inc. | Transgenic mouse having a disrupted amyloid precursor protein gene |
| EP0850051A2 (en) | 1995-08-31 | 1998-07-01 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| US6194177B1 (en) | 1996-02-20 | 2001-02-27 | Applied Research Systems Ars Holding N.V. | DNA encoding a hybrid heterodimeric protein |
| EP0906090A1 (en) | 1996-03-15 | 1999-04-07 | Somerset Pharmaceuticals, Inc. | Method for preventing and treating peripheral neurophathy by administering selegiline |
| US6358752B1 (en) | 1996-09-27 | 2002-03-19 | Cornell Research Foundation, Inc. | Liposome-enhanced test device and method |
| ATE355371T1 (de) | 1996-12-26 | 2006-03-15 | Kyowa Hakko Kogyo Kk | Protein having an activity of suppressing aging |
| US6127598A (en) | 1997-07-25 | 2000-10-03 | The Regents Of The University Of California | NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| US6537749B2 (en) | 1998-04-03 | 2003-03-25 | Phylos, Inc. | Addressable protein arrays |
| US7060479B2 (en) | 1999-12-08 | 2006-06-13 | Serono Genetics Institute, S.A. | Full-length human cDNAs encoding potentially secreted proteins |
| US20030055231A1 (en) | 1998-10-28 | 2003-03-20 | Jian Ni | 12 human secreted proteins |
| JP4585693B2 (ja) | 1999-04-22 | 2010-11-24 | リポサイエンス、インコーポレイテッド | Ｉｉ型糖尿病を発現する危険性のｎｍｒによる決定方法 |
| US6569832B1 (en) | 1999-11-12 | 2003-05-27 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
| US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
| US20060160181A1 (en) * | 2000-02-15 | 2006-07-20 | Amgen Inc. | Fibroblast Growth Factor-23 molecules and uses thereof |
| EP2075255A1 (en) | 2000-03-08 | 2009-07-01 | Novartis Vaccines and Diagnostics, Inc. | Human FGF-23 gene and gene expression products |
| CA2418215A1 (en) | 2000-07-19 | 2002-01-31 | Advanced Research & Technology Institute | Novel fibroblast growth factor (fgf23) and methods for use |
| US20030129686A1 (en) | 2001-01-30 | 2003-07-10 | Glass David J. | Novel nucleic acid and polypeptide molecules |
| US7588757B2 (en) | 2001-03-14 | 2009-09-15 | Genzyme Corporation | Methods of treating Parkinson's disease using recombinant adeno-associated virus virions |
| JP2006240990A (ja) * | 2003-05-15 | 2006-09-14 | Kirin Brewery Co Ltd | ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途 |
| WO2005037867A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
| JP2006158339A (ja) * | 2004-12-09 | 2006-06-22 | Kyoto Univ | βＫｌｏｔｈｏ遺伝子、Ｃｙｐ７ａ１遺伝子、及びそれらの利用 |
| US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
| TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| WO2009117622A2 (en) | 2008-03-19 | 2009-09-24 | Ambrx, Inc. | Modified fgf-23 polypeptides and their uses |
| NZ592009A (en) | 2008-10-10 | 2012-11-30 | Amgen Inc | Fgf21 mutants and uses thereof |
| AU2010246038A1 (en) | 2009-05-05 | 2011-12-01 | Amgen Inc. | FGF21 mutants and uses thereof |
| US8461111B2 (en) | 2009-05-20 | 2013-06-11 | Florida State University Research Foundation | Fibroblast growth factor mutants having improved functional half-life and methods of their use |
| US20110195077A1 (en) | 2010-01-29 | 2011-08-11 | Novartis Ag | Methods and compositions using fgf23 fusion ppolypeptides |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
-
2009
- 2009-01-22 TW TW098102662A patent/TW200936156A/zh unknown
- 2009-01-26 EP EP09706624.5A patent/EP2247614B1/en active Active
- 2009-01-26 CA CA2854933A patent/CA2854933A1/en not_active Abandoned
- 2009-01-26 KR KR1020107019047A patent/KR20100118126A/ko not_active Application Discontinuation
- 2009-01-26 MX MX2010008206A patent/MX2010008206A/es active IP Right Grant
- 2009-01-26 EA EA201001204A patent/EA201001204A1/ru unknown
- 2009-01-26 ES ES09706624.5T patent/ES2479417T3/es active Active
- 2009-01-26 JP JP2010543520A patent/JP5627469B2/ja not_active Expired - Fee Related
- 2009-01-26 BR BRPI0906722-1A patent/BRPI0906722A2/pt not_active IP Right Cessation
- 2009-01-26 AU AU2009209696A patent/AU2009209696B2/en not_active Ceased
- 2009-01-26 CN CN200980111072.0A patent/CN102015760B/zh not_active Expired - Fee Related
- 2009-01-26 CA CA2712634A patent/CA2712634C/en not_active Expired - Fee Related
- 2009-01-26 WO PCT/EP2009/050850 patent/WO2009095372A1/en active Application Filing
- 2009-01-27 PE PE2009000108A patent/PE20091405A1/es not_active Application Discontinuation
- 2009-01-27 CL CL2009000166A patent/CL2009000166A1/es unknown
- 2009-01-27 AR ARP090100247A patent/AR070690A1/es unknown
- 2009-01-28 US US12/360,970 patent/US8481031B2/en not_active Expired - Fee Related
-
2010
- 2010-07-19 MA MA33039A patent/MA32031B1/fr unknown
- 2010-07-21 CR CR11580A patent/CR11580A/es not_active Application Discontinuation
- 2010-07-22 IL IL207161A patent/IL207161A0/en unknown
- 2010-07-28 EC EC2010010372A patent/ECSP10010372A/es unknown
- 2010-07-28 CO CO10092102A patent/CO6300826A2/es not_active Application Discontinuation
-
2013
- 2013-05-29 US US13/904,574 patent/US9458209B2/en active Active